Nicolai Andersen - Coloplast A/S Senior Vice President Wound Care

CLPBF Stock  USD 128.57  7.42  6.12%   

President

Mr. Nicolai Buhl Andersen serves as Senior Vice President, Wound Care at Coloplast AS. He was employed at the Company since 2009. He completed Management Program at IMD Business School in 2007, studied at Copenhagen Business School and holds MS degree from Sophia University.
Age 54
Phone45 49 11 11 11
Webhttps://www.coloplast.com

Coloplast A/S Management Efficiency

The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast A/S's management efficiency ratios could be used to measure how well Coloplast A/S manages its routine affairs as well as how well it operates its assets and liabilities.
Coloplast AS has accumulated 16.36 B in total debt with debt to equity ratio (D/E) of 2.83, implying the company greatly relies on financing operations through barrowing. Coloplast A/S has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Coloplast A/S until it has trouble settling it off, either with new capital or with free cash flow. So, Coloplast A/S's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Coloplast A/S sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Coloplast to invest in growth at high rates of return. When we think about Coloplast A/S's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Christopher DelOreficeBecton Dickinson and
53
James LimBecton Dickinson and
56
Roland GoetteBecton Dickinson and
58
Samrat KhichiBecton Dickinson and
53
Christopher ReidyBecton Dickinson and
64
Patrick KaltenbachBecton Dickinson and
56
Paul MarcunColoplast A
56
James BorziBecton Dickinson and
49
Guillaume DaniellotStraumann Holding AG
53
Anders LonningSkovgaardColoplast A
51
David HickeyBecton Dickinson and
60
Thomas SpoerelBecton Dickinson and
45
John DeFordBecton Dickinson and
55
Betty LarsonBecton Dickinson and
44
Alberto MasBecton Dickinson and
59
Alain MorvanColoplast A
N/A
Alexandre ConroyBecton Dickinson and
57
Simon CampionBecton Dickinson and
49
Charles BodnerBecton Dickinson and
46
Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast is traded on OTC Exchange in the United States. Coloplast AS [CLPBF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Coloplast A/S Leadership Team

Elected by the shareholders, the Coloplast A/S's board of directors comprises two types of representatives: Coloplast A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast A/S's management team and ensure that shareholders' interests are well served. Coloplast A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ellen Bjurgert, VP Relations
Allan Rasmussen, Executive VP of Global Operations
Alain Morvan, Senior Vice President Sales Europe
Thomas Barfod, Director, Employee Representative
Nicolai Andersen, Senior Vice President Wound Care
Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management
Kristian Villumsen, Executive VP of Chronic Care
Paul Marcun, Senior Vice President Emerging Markets
Dorthe Ronnau, VP Culture
Dennis Kaysen, Director Communications

Coloplast Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Coloplast Pink Sheet

Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.